Oveporexton Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Oveporexton Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Oveporexton can convert its Small molecule drug profile and OX2R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Oveporexton (query alias: Oveporexton) |
|---|---|
| Modality / target | Small molecule drug; OX2R; OX2R agonists |
| Highest global status | NDA/BLA |
| Originator | Takeda Pharmaceutical Co., Ltd. |
| Active developers | Takeda Pharmaceutical Co., Ltd., Takeda Development Center Americas, Inc., Takeda Pharmaceuticals Australia Pty Ltd. |
The MCP disease footprint includes Narcolepsy, Cataplexy, Disorders of Excessive Somnolence. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06470828 | Phase 3 | Completed | 168 | Change From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake Trials |
| NCT06505031 | Phase 3 | Completed | 105 | Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials |
| NCT07363720 | Phase 3 | Recruiting | 88 | Time to Loss of Response in the Epworth Sleepiness Scale (ESS) Score During the Up to 4-Week RW Period |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
Phase 3; n=105; evaluation: not stated. Reported fields: Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials(Least Squares Mean) = -1.01 minutes (Standard Error, 1.529); Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials(Least Squares Mean) = 19.09 minutes (Standard Error, 1.254); Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials(Least Squares Mean): LS Mean Difference = 20.09(95% CI, 16.57 - 23.61), P-Value = <0.001
武田制药在2025年世界睡眠大会上公布针对1型发作性睡病 具有里程碑意义的Oveporexton（TAK-861）3期临床研究食欲素数据
临床3期; n=273; evaluation: 积极. Reported fields: ESS评分(第12周) = 85 % 达到; ESS评分(第12周) = 近85%的受试者与健康个体相当（≤10）。 % 达到
武田宣布Oveporexton （TAK-861）治疗1型发作性睡病的两项关键性3期研究取得积极结果
临床3期; n=not disclosed; evaluation: 积极. Reported fields: 主要终点 = 相比安慰剂组均取得了具有统计学显著性的改善 达到; 主要终点 = 相比安慰剂组均取得了具有统计学显著性的改善 达到
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Oveporexton addresses Narcolepsy, Cataplexy, Disorders of Excessive Somnolence. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 21 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: OX2R records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-03-31 | Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | Phase 2 | Financial terms not disclosed |
| 2026-03-11 | Idorsia and Pharmalink sign agreement to distribute Quviviq | Approved | Financial terms not disclosed |
| 2026-02-26 | Sumitomo Pharma announced the termination of License Agreement for Selective Orexin 2 Receptor Agonist DSP‑0187 | Phase 1 | US$50.0M upfront; US$1,090.0M milestones; US$1,140.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
